Roche Using SNALPs with First RNAi Rx Candidate, Optimizing In-House Delivery Tech

Meanwhile, the Swiss drugs and diagnostics giant is taking a measured approach to the related but nascent microRNA field, exploring partnerships with key miRNA companies and doing a certain amount of research on its own, yet keeping most of its attention focused on RNAi.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.